January 31, 2022
BHI’s next EIR Feedback Day is February 16th
These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and…
January 31, 2022
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md.,…
January 31, 2022
BioHealth Innovation Announces Updates to its Board of Directors
Board of Directors Elects New Chair, Vice-Chair, and Two New Members ROCKVILLE, MARYLAND, January 31, 2021 – The Board of…
January 31, 2022
Opportunity: Entrepreneur-In-Residence Role with BioHealth Innovation, Inc. and NIH
POSITION DESCRIPTION – Entrepreneur-In-Residence EIRs will work in collaboration with SEED to mentor innovators and provide guidance to help them…
January 31, 2022
5 Cities Emerging As Future Hubs For Life Sciences Development
The current boom in life sciences development mirrors the tech industry, especially geographically; there is an incredible concentration of jobs…
January 31, 2022
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine
The Novavax vaccine would be the first protein-based alternative available in Israel GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- Novavax,…
January 31, 2022
Maryland life science & digital health companies drive record VC investment. | Maryland Business News
In 2021, venture capitalists invested $2.27 billion in Maryland companies, according to the initial figures from the PitchBook-NVCA Venture Monitor…
January 31, 2022
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma :: Immunocore PLC
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, Wednesday, January 26, 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or…